宫内放置曼月乐宫内节育环治疗子宫腺肌症的效果  

Efficacy of Intrauterine Device of Mirena in Treatment of Adenomyosis

作　　者：豆灵灵 DOU Lingling(Department of Obstetrics and Gynecology,Yongcheng Central Hospital,Yongcheng Henan 476600,China)

机构地区：[1]永城市中心医院妇产科

出　　处：《河南医学高等专科学校学报》2019年第5期602-605,共4页Journal of Henan Medical College

摘　　要：目的探求子宫腺肌症采用宫内放置曼月乐宫内节育环治疗对其效果、月经及基础性激素的影响。方法选取102例子宫腺肌症患者,按抽签法分为对照组和观察组,各51例。对照组采用米非司酮治疗,观察组采用曼月乐宫内节育环治疗,6个月后,比较2组疗效、痛经视觉模拟评分(visual analogues scales,VAS)、月经量月经失血图(pictorial blood loss assessment chart,PBAC)评分、基础性激素及不良反应率。结果治疗后,观察组总有效率94.12%、雌二醇(E 2)水平(95.65±7.41)nmol/L、促黄体生成素(LH)(9.26±1.14)IU/L、促卵泡激素(FSH)(10.01±2.09)IU/L、睾酮(T)(3.54±0.31)nmol/L、泌乳素(PRL)(209.63±20.31)μIU/L及促甲状腺素(TSH)(7.22±2.02)mol/L,高于对照组的80.39%、(76.25±7.47)nmol/L、(7.06±1.34)IU/L、(8.35±2.11)IU/L、(2.41±0.26)nmol/L、(186.37±21.03)μIU/L及(6.14±1.53)mol/L,差异有统计学意义(P<0.01);观察组VAS评分(2.04±0.96)分、月经量PBAC评分(62.85±15.74)分,低于对照组的(3.28±0.84)分、(80.32±16.24)分,差异均有统计学意义(P<0.01);2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论子宫腺肌症采用宫内放置曼月乐宫内节育环治疗可提升临床疗效,改善痛经程度及月经量,对基础性激素影响较小,且不良反应较少。Objective To investigate the influence of intrauterine device of Mirena on the efficacy,menstruation and ovarian function in patients with adenomyosis.Methods 102 patients with adenomyosis were selected,and they were divided into control group(51 cases)and research group(51 cases)by draw lots.Control group was treated with mifepristone,while research group was given intrauterine device of Mirena.After 6 months,the efficacy,menstruation,ovarian function,adverse reactions were compared between the two groups.Results After treatment,the total effective rate was 94.12%.In research group,E2(95.65±7.41)nmL/L,LH(9.26±1.14)IU/L,FSH(10.01±2.09)IU/L,T(3.54±0.31)nmol/L,PRL(209.63±20.31)μIU/L,TSH(7.22±2.02)moI/L were higher than those in the control group(80.39%),(76.25±7.47)nmol/L,(7.06±1.34)IU/L,(8.35±2.11)IU/L,(2.41±0.26)nmol/L,(186.37±21.03)μIU/L,(6.14±1.53)mol/L.There was statistical significance(P<0.01).In the research group,visual analogue scoring(VAS)criteria for dysmenorhea was(2.04±0.96),scoring criteria for menstral volum(PBAC)was(62.85±15.74),lower than those of in the control group(3.28±0.84),(80.32±16.24).There was statistical significance(P<0.01).There was no statistical significance in adverse reaction rate for both groups.There was no statistical significance(P>0.05).Conclusion Intrauterine device of Mirena in the treatment of adenomyosis can increase clinical efficacy,improve dysmenorrhea and menstrual blood volume,and has less influence on ovarian function,adverse reactions.

关 键 词：子宫腺肌症 宫内放置曼月乐环 月经 基础性激素 

分 类 号：R711.74[医药卫生—妇产科学]